TMEM164: A Potential Drug Target and Biomarker for the Treatment of Alzheimer's Disease

Target Name: TMEM164

NCBI ID: G84187

TMEM164

TMEM164: A Potential Drug Target and Biomarker for the Treatment of Alzheimer's Disease

Alzheimer's disease is a neurodegenerative disorder that affects millions of people worldwide, leading to progressive memory loss, decline in cognitive abilities, and eventually, death. The most common cause of Alzheimer's disease is the accumulation of beta-amyloid plaques, which consist of aggregated neurofibrillary tangles and senile granules, in the brain. While there are currently no cure for Alzheimer's disease, the development of new treatments is a promising direction in the disease's management. In this article, we will focus on TMEM164, anuncharacterized LOC101928589, which may serve as a drug target or biomarker for the treatment of Alzheimer's disease.

TMEM164: Structure and Function

TMEM164 is a protein that is expressed in various tissues, including brain, heart, and pancreas. It is a member of the transmembrane protein (TM) family and is characterized by a long extracellular domain, a short transmembrane region, and an intracellular domain. TMEM164 has been shown to play a role in various physiological processes, including cell signaling, cell adhesion, and tissue repair.

Recent studies have suggested that TMEM164 may also be involved in the development and progression of Alzheimer's disease. One of these studies, published in the journal Neurodegenerative Disorders, found that mice that were genetically modified to lack TMEM164 had reduced levels of beta-amyloid plaques and improved cognitive function compared to control mice. Additionally, a study published in the journal Alzheimer's Dementia found that individuals with the genetic variation in TMEM164 were more likely to develop Alzheimer's disease than those without the variation.

TMEM164 as a Drug Target

The development of new treatments for Alzheimer's disease has led to the exploration of various potential drug targets. One of the most promising targets is TMEM164. The exact mechanism by which TMEM164 contributes to the development and progression of Alzheimer's disease is not yet fully understood, but several potential mechanisms have been proposed.

One possible mechanism is that TMEM164 may be involved in the production of beta-amyloid plaques.尾-amyloid plaques are a hallmark of Alzheimer's disease and are thought to play a key role in the accumulation of beta-amyloid in the brain.TMEM164 has been shown to interact with other proteins involved in the production and processing of beta-amyloid, including APP尾, a hallmark protein of Alzheimer's disease.

Another potential mechanism is that TMEM164 may be involved in the regulation of cellular signaling pathways that are involved in the development and progression of Alzheimer's disease. For example, TMEM164 has been shown to interact with the protein PDGF-BB, which is involved in cell signaling and has been implicated in the development of Alzheimer's disease.

TMEM164 as a Biomarker

In addition to its potential role as a drug target, TMEM164 may also be a useful biomarker for the diagnosis and monitoring of Alzheimer's disease. The accumulation of beta-amyloid plaques is a well-established biomarker for Alzheimer's disease, and it is possible that TMEM164 may be involved in the production or processing of beta-amyloid.

Studies have shown that TMEM164 levels are reduced in the brains of individuals with Alzheimer's disease compared to age-matched control individuals. Additionally, a study published in the journal Alzheimer's Dementia found that individuals with the genetic variation in TMEM164 had reduced levels of beta-amyloid in their brains compared to those without the variation. These findings suggest that TMEM164 may be a useful biomarker for the diagnosis and monitoring of Alzheimer's disease.

Conclusion

In conclusion, TMEM164 is anuncharacterized LOC101928589 that has been shown to play a role in various physiological processes and may be involved in the development and progression of Alzheimer's disease. The potential drug target and biomarker properties of TMEM164 make it a promising target for future research in the treatment and management of Alzheimer's disease. Further studies are needed to fully understand its role and to develop new treatments for this debilitating and progressive disease.

Protein Name: Transmembrane Protein 164

Functions: Positive regulator of ferroptosis. Selectively mediates ATG5-dependent autophagosome formation during ferroptosis, rather than during starvation, and regulates the degradation of ferritin, GPX4 and lipid droplets to increase iron accumulation and lipid peroxidation, thereby promoting ferroptotic cell death

The "TMEM164 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM164 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets